ALGS Q1 2026 Earnings NarrowerthanExpected Loss as Aligos Therapeutics Advances Pipeline PMV Pharmaceuticals PMVP Q1 2026 Earnings Narrower Loss Provides a Glimmer of Operational Efficiency Fate Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Lifts Shares 7 DVS Q4 2025 Earnings Silver Developer Reports WiderThanExpected Loss Amid PreRevenue Phase BCSF Q1 2026 Earnings Slight EPS Miss Amid Stable Portfolio Performance CCAP Q1 2026 Earnings Narrow EPS Miss Highlights Steady Portfolio Returns